Poland Dermatology Drugs Market Analysis Report 2022 to 2030

Poland Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Poland Dermatology drugs market will reach a value of $xx Mn from $98.6 Mn in 2022, growing at a CAGR of xx% during 2022-30. The market is primarily dominated by local players such as Centrum Medyczne Dermiq, Novoxidyl, and Ita-Test Laboratory. The market is driven by government regulations, increasing the prevalence of disease, and health indicators in the country. The dermatology drug market in Poland is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10PLPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Poland AUTHOR: Dr. Vishwa Modhia

Buy Now

Poland Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Poland Dermatology drugs market will reach a value of $xx Mn from $98.6 Mn in 2022, growing at a CAGR of xx% during 2022-30.

As of my knowledge cut-off in 2021, the prevalence of dermatological diseases in Poland was high, with a significant number of people affected by various skin conditions such as acne, eczema, psoriasis, and skin cancer. The high prevalence of dermatological diseases in Poland was attributed to several factors, including increasing levels of air pollution, exposure to UV radiation, and a growing population of aging individuals who are more susceptible to skin problems.

Poland's decentralized healthcare system struggles to be efficient and available to all of its citizens, claims a 2017 OECD report. For the vast majority of its citizens, Poland provides free healthcare that is funded by the government. The Polish government invested 6.5% of its GDP in healthcare in 2019.

Market Dynamics

Market Growth Drivers

The high prevalence of dermatological conditions in Poland has also been linked to lifestyle factors like smoking, stress, and a poor diet. The market for dermatology medications in Poland is being driven by an increase in cases of various dermatological conditions.

Market Restraints

Due to high rates of spending on both prescription drugs and over-the-counter medications, 30% of current healthcare spending is private, a higher percentage than in the rest of the EU. When it comes to access and care quality, there is a significant disparity between income groups in Poland.

Competitive Landscape

Key Players

Ita-Test laboratory (POL)
Novoxidyl (POL)
Centrum Medyczne Dermiq (POL)
High-Med. Przychodnia Specjalistyczna (POL)
GlaxoSmithKline
Pfizer
Sanofi
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

The Chief Pharmaceutical Inspectorate (GIF), which is in charge of examining and registering medicines in Poland, oversees the regulation of dermatology medications there. The GIF is in charge of ensuring the efficacy, quality, and safety of medicines as well as keeping an eye on how they are used on the market.

The National Health Fund (NFZ), which is in charge of funding the nation's healthcare system, is in charge of managing dermatology drug reimbursement in Poland. The national health insurance system's approved list of medications is determined by the NFZ, which also establishes the cost of each drug's reimbursement. Dermatology medications must be approved by the Chief Pharmaceutical Inspectorate (GIF) and listed among the medicinal products that are eligible for reimbursement before they can be paid for. The effectiveness, safety, and cost-effectiveness of the drug are just a few of the considerations that go into the reimbursement decision.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.